Clinical Trial

Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)

Study acronym: ALDORA
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluation of spironolactone, a well-known cardiological treatment, in patients with rheumatoid arthritis (RA). The hypothesis is that spironolactone, through its anti-inflammatory and anti-fibrosis actions, decreases RA's activity. The primary objective is to assess the efficacy of spironolactone on RA activity by evaluating the proportion of patients achieving DAS28-CRP \< 3.2 at 3 months (comparison between spironolactone and placebo arms). CRP (C reactive protein)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-10-12; most recent amendment 2025-03-10.
Status change: Not Yet Recruiting → Recruiting 2022-08-17
Trial Details
NCT Number NCT05092984
Lead Sponsor University Hospital, Strasbourg, France
Conditions Rheumatoid Arthritis
Enrollment 154 participants
Start Date 2022-06-22
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-03-12